DARA BioSciences, Inc. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “DARA BioSciences, Inc. - Product Pipeline Review - H2 2011” provides data on the DARA BioSciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, DARA BioSciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from DARA BioSciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “DARA BioSciences, Inc. - Product Pipeline Review - H2 2011” provides data on the DARA BioSciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, DARA BioSciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from DARA BioSciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- DARA BioSciences, Inc. - Brief DARA BioSciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of DARA BioSciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of DARA BioSciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the DARA BioSciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate DARA BioSciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of DARA BioSciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the DARA BioSciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with DARA BioSciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of DARA BioSciences, Inc. and identify potential opportunities in those areas.
DARA BioSciences, Inc. Snapshot
DARA BioSciences, Inc. Overview
Key Information
Key Facts
DARA BioSciences, Inc. – Research and Development Overview
Key Therapeutic Areas
DARA BioSciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
DARA BioSciences, Inc. – Pipeline Products Glance
DARA BioSciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
DARA BioSciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
DARA BioSciences, Inc. – Drug Profiles
DB160
Product Description
Mechanism of Action
R&D Progress
DB200
Product Description
Mechanism of Action
R&D Progress
DB900
Product Description
Mechanism of Action
R&D Progress
DB959
Product Description
Mechanism of Action
R&D Progress
KRN5500
Product Description
Mechanism of Action
R&D Progress
DARA BioSciences, Inc. – Pipeline Analysis
DARA BioSciences, Inc. – Pipeline Products by Therapeutic Class
DARA BioSciences, Inc. - Pipeline Products By Target
DARA BioSciences, Inc. – Pipeline Products by Route of Administration
DARA BioSciences, Inc. – Pipeline Products by Molecule Type
DARA BioSciences, Inc. – Recent Pipeline Updates
DARA BioSciences, Inc. - Dormant Projects
DARA BioSciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
PT-100
PT-100 + Cisplatin
Talabostat + Docetaxel
Talabostat + Gemcitabine
Talabostat + Pemetrexed Disodium
Talabostat + Rituximab
DARA BioSciences, Inc. – Company Statement
DARA BioSciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mar 30, 2009: DARA BioSciences Presents Abstracts For DB959 At American Diabetes Association Scientific Sessions
Mar 29, 2011: DARA Reports Promising Findings From Phase II Study Of KRN5500 at ADEPT
Jun 28, 2011: DARA BioSciences Presents Positive Results Of Phase I Study For DB959 At American Diabetes Association Scientific Session
Apr 27, 2010: DARA Partners With Division Of Cancer Prevention, National Cancer Institute For Clinical Development Of KRN5500
Mar 26, 2010: DARA BioSciences Initiates Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Feb 22, 2010: DARA BioSciences' Clinical Study Results For KRN5500 Selected For Presentation At CHI's Annual 'Targeting Pain with Novel Therapeutics" Meeting
Jun 21, 2011: DARA BioSciences To Present Positive Results Of DB959 Phase I Study At Upcoming 71st ADA Scientific Sessions
Apr 21, 2011: DARA To Present Results Of DB959 Phase I Study At 71st ADA Scientific Sessions
Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced Neuropathic Pain In Patients With Cancer
Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit
Sep 15, 2009: DARA BioSciences Presents Phase 2a Study Results For KRN5500 At the "12th International Conference On The Mechanisms And Treatment Of Neuropathic Pain" Meeting
Dec 14, 2010: DARA BioSciences Reports Positive Phase II Data Of KRN5500 In Neuropathic Pain
Jul 14, 2009: DARA BioSciences Releases Promising Preclinical Data For DB959 For Type 2 Diabetes .
Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients With Cancer
Mar 10, 2009: United States Food And Drug Administration Approves DARA Investigational New Drug Application (IND) For DB959.
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer
Apr 05, 2011: DARA BioSciences Initiates Phase Ib Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Jan 05, 2011: DARA Provides Additional Details From Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Nov 04, 2010: DARA BioSciences Successfully Completes Phase I Clinical Study Of DB959 for Treatment Of Type 2 Diabetes
Nov 01, 2011: DARA Announces Positive Results From Successfully Completed Phase Ib Clinical Study Of DB959 In Type 2 Diabetes
Feb 01, 2011: DARA's KRN5500 Study Results Selected For Presentation By International Conference On Accelerating Development Of Enhanced Pain Treatments
Financial Deals Landscape
DARA BioSciences, Inc., Deals Summary
DARA BioSciences, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
DARA BioSciences Enters Into Co-Development Agreement With NCE Discovery
Point Therapeutics Enters Into Co-Development Agreement With National Cancer Institute
Licensing Agreements
DARA BioSciences Enters Into Licensing Agreement With Kirin Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Bayer Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Nuada
Equity Offering
DARA BioSciences Files Registration Statement For Public Offering Of $30 Million
DARA BioSciences Completes Public Offering Of Units For $4.8 Million
DARA BioSciences Completes Registered Direct Offering Of Units For $1.4 Million
DARA BioSciences Completes Private Placement Of $1.72 Million
DARA BioSciences Completes Private Placement Of $0.75 Million
DARA BioSciences Completes Registered Direct Offering Of $1.21 Million
DARA BioSciences Completes Registered Direct Offering Of $2.5 Million
DARA BioSciences Completes Private Placement Of $1.4 Million
DARA Biosciences Completes Private Placement Of $2.26 Million
Point Therapeutics Completes Registered Direct Offering Of $4.76 Million
Point Therapeutics Completes Public Offering Of $28 Million
Point Therapeutics Completes Registered Direct Offering Of $16 Million
Point Therapeutics Completes Private Placement Of $13.5 Million
Acquisition
Point Therapeutics Acquires DARA BioSciences
DARA BioSciences Acquires Minority Stake In Medeikon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
DARA BioSciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
DARA BioSciences, Inc. – Pipeline by Stage of Development, H2 2011
DARA BioSciences, Inc. - Phase II, H2 2011
DARA BioSciences, Inc. - Pipeline By Therapeutic Class, H2 2011
DARA BioSciences, Inc. - Pipeline By Target, H2 2011
DARA BioSciences, Inc. – Pipeline By Route of Administration, H2 2011
DARA BioSciences, Inc. – Pipeline By Molecule Type, H2 2011
DARA BioSciences, Inc. – Recent Pipeline Updates, H2 2011
DARA BioSciences, Inc. - Dormant Developmental Projects, 2010
DARA BioSciences, Inc. - Discontinued Pipeline Products, 2010
DARA BioSciences, Inc., Subsidiaries
DARA BioSciences, Inc., Deals Summary
DARA BioSciences Enters Into Co-Development Agreement With NCE Discovery
Point Therapeutics Enters Into Co-Development Agreement With National Cancer Institute
DARA BioSciences Enters Into Licensing Agreement With Kirin Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Bayer Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Nuada
DARA BioSciences Files Registration Statement For Public Offering Of $30 Million
DARA BioSciences Completes Public Offering Of Units For $4.8 Million
DARA BioSciences Completes Registered Direct Offering Of Units For $1.4 Million
DARA BioSciences Completes Private Placement Of $1.72 Million
DARA BioSciences Completes Private Placement Of $0.75 Million
DARA BioSciences Completes Registered Direct Offering Of $1.21 Million
DARA BioSciences Completes Registered Direct Offering Of $2.5 Million
DARA BioSciences Completes Private Placement Of $1.4 Million
DARA Biosciences Completes Private Placement Of $2.26 Million
Point Therapeutics Completes Registered Direct Offering Of $4.76 Million
Point Therapeutics Completes Public Offering Of $28 Million
Point Therapeutics Completes Registered Direct Offering Of $16 Million
Point Therapeutics Completes Private Placement Of $13.5 Million
Point Therapeutics Acquires DARA BioSciences
DARA BioSciences Acquires Minority Stake In Medeikon
LIST OF FIGURES
DARA BioSciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
DARA BioSciences, Inc. – Pipeline by Stage of Development, H2 2011
DARA BioSciences, Inc. - Pipeline By Target, H2 2011
DARA BioSciences, Inc. – Pipeline By Route of Administration, H2 2011
DARA BioSciences, Inc. – Pipeline By Molecule Type, H2 2011
DARA BioSciences, Inc. Overview
Key Information
Key Facts
DARA BioSciences, Inc. – Research and Development Overview
Key Therapeutic Areas
DARA BioSciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
DARA BioSciences, Inc. – Pipeline Products Glance
DARA BioSciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
DARA BioSciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
DARA BioSciences, Inc. – Drug Profiles
DB160
Product Description
Mechanism of Action
R&D Progress
DB200
Product Description
Mechanism of Action
R&D Progress
DB900
Product Description
Mechanism of Action
R&D Progress
DB959
Product Description
Mechanism of Action
R&D Progress
KRN5500
Product Description
Mechanism of Action
R&D Progress
DARA BioSciences, Inc. – Pipeline Analysis
DARA BioSciences, Inc. – Pipeline Products by Therapeutic Class
DARA BioSciences, Inc. - Pipeline Products By Target
DARA BioSciences, Inc. – Pipeline Products by Route of Administration
DARA BioSciences, Inc. – Pipeline Products by Molecule Type
DARA BioSciences, Inc. – Recent Pipeline Updates
DARA BioSciences, Inc. - Dormant Projects
DARA BioSciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
PT-100
PT-100 + Cisplatin
Talabostat + Docetaxel
Talabostat + Gemcitabine
Talabostat + Pemetrexed Disodium
Talabostat + Rituximab
DARA BioSciences, Inc. – Company Statement
DARA BioSciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mar 30, 2009: DARA BioSciences Presents Abstracts For DB959 At American Diabetes Association Scientific Sessions
Mar 29, 2011: DARA Reports Promising Findings From Phase II Study Of KRN5500 at ADEPT
Jun 28, 2011: DARA BioSciences Presents Positive Results Of Phase I Study For DB959 At American Diabetes Association Scientific Session
Apr 27, 2010: DARA Partners With Division Of Cancer Prevention, National Cancer Institute For Clinical Development Of KRN5500
Mar 26, 2010: DARA BioSciences Initiates Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Feb 22, 2010: DARA BioSciences' Clinical Study Results For KRN5500 Selected For Presentation At CHI's Annual 'Targeting Pain with Novel Therapeutics" Meeting
Jun 21, 2011: DARA BioSciences To Present Positive Results Of DB959 Phase I Study At Upcoming 71st ADA Scientific Sessions
Apr 21, 2011: DARA To Present Results Of DB959 Phase I Study At 71st ADA Scientific Sessions
Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced Neuropathic Pain In Patients With Cancer
Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit
Sep 15, 2009: DARA BioSciences Presents Phase 2a Study Results For KRN5500 At the "12th International Conference On The Mechanisms And Treatment Of Neuropathic Pain" Meeting
Dec 14, 2010: DARA BioSciences Reports Positive Phase II Data Of KRN5500 In Neuropathic Pain
Jul 14, 2009: DARA BioSciences Releases Promising Preclinical Data For DB959 For Type 2 Diabetes .
Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients With Cancer
Mar 10, 2009: United States Food And Drug Administration Approves DARA Investigational New Drug Application (IND) For DB959.
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer
Apr 05, 2011: DARA BioSciences Initiates Phase Ib Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Jan 05, 2011: DARA Provides Additional Details From Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes
Nov 04, 2010: DARA BioSciences Successfully Completes Phase I Clinical Study Of DB959 for Treatment Of Type 2 Diabetes
Nov 01, 2011: DARA Announces Positive Results From Successfully Completed Phase Ib Clinical Study Of DB959 In Type 2 Diabetes
Feb 01, 2011: DARA's KRN5500 Study Results Selected For Presentation By International Conference On Accelerating Development Of Enhanced Pain Treatments
Financial Deals Landscape
DARA BioSciences, Inc., Deals Summary
DARA BioSciences, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
DARA BioSciences Enters Into Co-Development Agreement With NCE Discovery
Point Therapeutics Enters Into Co-Development Agreement With National Cancer Institute
Licensing Agreements
DARA BioSciences Enters Into Licensing Agreement With Kirin Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Bayer Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Nuada
Equity Offering
DARA BioSciences Files Registration Statement For Public Offering Of $30 Million
DARA BioSciences Completes Public Offering Of Units For $4.8 Million
DARA BioSciences Completes Registered Direct Offering Of Units For $1.4 Million
DARA BioSciences Completes Private Placement Of $1.72 Million
DARA BioSciences Completes Private Placement Of $0.75 Million
DARA BioSciences Completes Registered Direct Offering Of $1.21 Million
DARA BioSciences Completes Registered Direct Offering Of $2.5 Million
DARA BioSciences Completes Private Placement Of $1.4 Million
DARA Biosciences Completes Private Placement Of $2.26 Million
Point Therapeutics Completes Registered Direct Offering Of $4.76 Million
Point Therapeutics Completes Public Offering Of $28 Million
Point Therapeutics Completes Registered Direct Offering Of $16 Million
Point Therapeutics Completes Private Placement Of $13.5 Million
Acquisition
Point Therapeutics Acquires DARA BioSciences
DARA BioSciences Acquires Minority Stake In Medeikon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
DARA BioSciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
DARA BioSciences, Inc. – Pipeline by Stage of Development, H2 2011
DARA BioSciences, Inc. - Phase II, H2 2011
DARA BioSciences, Inc. - Pipeline By Therapeutic Class, H2 2011
DARA BioSciences, Inc. - Pipeline By Target, H2 2011
DARA BioSciences, Inc. – Pipeline By Route of Administration, H2 2011
DARA BioSciences, Inc. – Pipeline By Molecule Type, H2 2011
DARA BioSciences, Inc. – Recent Pipeline Updates, H2 2011
DARA BioSciences, Inc. - Dormant Developmental Projects, 2010
DARA BioSciences, Inc. - Discontinued Pipeline Products, 2010
DARA BioSciences, Inc., Subsidiaries
DARA BioSciences, Inc., Deals Summary
DARA BioSciences Enters Into Co-Development Agreement With NCE Discovery
Point Therapeutics Enters Into Co-Development Agreement With National Cancer Institute
DARA BioSciences Enters Into Licensing Agreement With Kirin Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Bayer Pharmaceuticals
DARA BioSciences Enters Into Licensing Agreement With Nuada
DARA BioSciences Files Registration Statement For Public Offering Of $30 Million
DARA BioSciences Completes Public Offering Of Units For $4.8 Million
DARA BioSciences Completes Registered Direct Offering Of Units For $1.4 Million
DARA BioSciences Completes Private Placement Of $1.72 Million
DARA BioSciences Completes Private Placement Of $0.75 Million
DARA BioSciences Completes Registered Direct Offering Of $1.21 Million
DARA BioSciences Completes Registered Direct Offering Of $2.5 Million
DARA BioSciences Completes Private Placement Of $1.4 Million
DARA Biosciences Completes Private Placement Of $2.26 Million
Point Therapeutics Completes Registered Direct Offering Of $4.76 Million
Point Therapeutics Completes Public Offering Of $28 Million
Point Therapeutics Completes Registered Direct Offering Of $16 Million
Point Therapeutics Completes Private Placement Of $13.5 Million
Point Therapeutics Acquires DARA BioSciences
DARA BioSciences Acquires Minority Stake In Medeikon
LIST OF FIGURES
DARA BioSciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
DARA BioSciences, Inc. – Pipeline by Stage of Development, H2 2011
DARA BioSciences, Inc. - Pipeline By Target, H2 2011
DARA BioSciences, Inc. – Pipeline By Route of Administration, H2 2011
DARA BioSciences, Inc. – Pipeline By Molecule Type, H2 2011
